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Abstract
Background: Tanzania is among Sub-Saharan countries mostly affected by the HIV and AIDS pandemic, females
being more vulnerable than males. HIV infected women appear to have a higher rate of persistent infection by
high risk types of human papillomavirus (HPV) strongly associated with high-grade squamous intraepithelial lesions
(HSIL) and invasive cervical carcinoma. Furthermore, although HIV infection and cervical cancer are major public
health problems, the frequency and HIV/HPV association of cervical cancer and HSIL is not well documented in
Tanzania, thus limiting the development of preventive and therapeutic strategies.
Methods: A prospective unmatched, case-control study of HIV-seropositive, ≥ 18 years of age and consenting non-
pregnant patients attending the care and treatment center (CTC) at Muhimbili National Hoospital (MNH) as cases
was done between 2005 and 2006. HIV seronegative, non-pregnant and consenting women recruited from the
Cervical Cancer Screening unit (CCSU) at ORCI were used as controls while those who did not consent to study
participation and/or individuals under < 18 years were excluded. Pap smears were collected for routine
cytodiagnosis and P53 immunohistochemistry (IHC). Cervical lesions were classified according to the Modified
Bethesda System.
Results: A total of 170 participants from the two centers were recruited including 50 HIV-seronegative controls
were from the CCSU. Ages ranged from 20-66 years (mean 40.5 years) for cases and 20-69 years (mean 41.6 years)
for controls. The age group 36-45 years was the most affected by HIV (39.2%, n = 47). Cervicitis, squamous
intraepithelial lesions (SIL) and carcinoma constituted 28.3% (n = 34), 38.3% (n = 46) and 5.8% (n = 7) respectively
among cases, and 28% (n = 14), 34% (n = 17) and 2% (n = 1) for controls, although this was not statistically
significant (P-value = 0.61). IHC showed that p53 was not detectable in HPV + Pap smears and cell blocks
indicating possible degradation.
Conclusions: The frequency of SIL and carcinoma appeared to be higher among HIV-infected women on HAART
compared to seronegative controls and as expected increased with age. HIV seropositive patients appeared to
present earlier with SIL compared to those HIV seronegative suggesting a role of HIV in altering the natural history
of HPV infection and cervical lesions. The absence of p53 immunoreactivity in HPV + lesions is indicative of the
ability of HPV E6 proteins to interact with the tumor suppressor gene and pave way for viral-induced oncogenesis
in the studied Tanzanian women.
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Cancer of the uterine cervix remains the second com-
monest cancer among women worldwide [1], more
than 85% of the global burden of this disease occurs in
the developing world [1] being the commonest malig-
nancy in women in Sub-Saharan Africa according to
Globocan 2008 (IARC) [2]. The introduction of the
Papanicolaou (Pap) smear in 1930’s made early detec-
tion and treatment of pre-invasive disease possible,
which has significantly reduced morbidity and mortal-
ity related to cervical cancer in developed but not
developing countries, due to the absence of effective
screening programs [3]. HIV-infected women have a
higher likelihood of developing persistent high-risk
human papillomavirus (HPV) infection, precancer
[high-grade squamous intraepithelial lesions (HSIL)],
and invasive cervical cancer than seronegative women
but this has not been clearly documented in Tanzania
[1,4]. Furthermore, HIV-associated cervical lesions are
multicentric, aggressive and recurrent after treatment
[5]. Co-infection with HPV and HIV is to be expected
and recent epidemiological data from Africa show that
cervical cancer is the most common AIDS defining
neoplasm in women [5]. Among women infected with
HIV there is a high prevalence of HPV infection [6].
Unlike other AIDS defining neoplasms, the occurrence
of cervical cancer is not dependent on immune com-
promise [5]. It is established that invasive cervical can-
cer is the end result of progressive changes, beginning
with precursor lesions namely cervical dysplasia or cer-
vical intraepithelial neoplasia (CIN) also called squa-
mous intraepithelial lesion (SIL), carcinoma in-situ
(CIS) and lastly invasive carcinoma [7]. However, if
early detection is made, pre-malignant lesions are
reversible and cure of early-stage cancer is achievable.
A number of risk factors that contribute to the devel-
opment of cervical cancer, including low socioeco-
nomic class, sexual intercourse at an early age,
multiple sexual partners, multiparity, long-term oral
contraceptive use, tobacco smoking, vitamin deficiency
and sexually transmitted infection (STI) including
Chlamydia trachomatis and Herpes virus type II have
been identified [8-10] including the human papilloma
virus (HPV) as a primary sexually transmitted etiologic
agent in the development of cervical squamous cell
carcinoma (CSCC) and its precursors [11]. Further-
more, HIV-related immunosuppression seems to con-
tribute to increased frequency of SIL and HSIL as
previously reported from Tanzania although that study
did not include invasive cancer [12]. HIV infection and
cervical cancer are major public health problems
among women in Tanzania, although, the frequency of
cervical cancer and pre-cancerous lesions in the
general compared to the HIV-infected populations in
Tanzania is not well documented and is elucidated in
the current study.
Methods
Study area
The study was conducted in the Unit of Histopathology/
Morbid Anatomy as well as the Department Obstetrics/
Gynaecology at the Muhimbili National Hospital
(MNH), Dar es Salaam, Tanzania in collaboration with
the Cervical Cancer Screening Unit (CCSU) at the
Ocean Road Cancer Institute (ORCI).
Study design and sampling criteria
This was a prospective unmatched, case-control study of
HIV-seropositive, ≥ 18 years of age and consenting non-
pregnant patients attending the care and treatment cen-
ter (CTC) for highly active antiretroviral therapy
(HAART) at MNH as cases was done between 2005 and
2006. HIV seronegative, non-pregnant and consenting
women recruited from the Cervical Cancer Screening
unit (CCSU) at ORCI were controls while those who
did not consent to study participation and/or individuals
under < 18 years were excluded. Thus all women meet-
ing these criteria at the two centres during the study
period were included the sample prospectively.
Laboratory methods
HIV serology
HIV-1 evaluation was done at the Department of Micro-
biology/Immunology, Muhimbili University of Health
and Allied Sciences (MUHAS) and was performed on
sera as previously described [13,14] and results obtained
through the medical records departments of MNH and
ORCI.
Pap smears
Pap smears were performed by a Gynaecologist at the
MNH and ORCI clinics. Patients were put in lithotomy
position and a bivalve speculum was introduced. The
cervix was exposed under illumination for assessment.
Specimens were taken from the squamo-columnar junc-
tion using an Ayres spatula. The specimens were
smeared on five SuperFrost
® glass slides (Menzel GmbH
& Co KG, Braunschweigh, Germany) two of them fixed
immediately in 95% alcohol/ether for Papanicolaou
staining (see below) and the rest air dried for two hours
for immunocytochemistry. Slides were examined under
a light microscope and cytodiagnosis done by a
Pathologist.
Papanicolau staining procedure
Alcohol/ether-fixed smears were hydrated in graded
alcohol as previously described [15] and stained with
Harris Haematoxylin for 5 minutes, differentiated in
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water for 3 minutes. Smears were then dehydrated in
ascending graded alcohol from 70% to 95% and stained
with orange G for 3 minutes, rinsed in 95% alcohol fol-
lowed by staining with EA 36 for three minutes and
then dehydrated in absolute alcohol. Thereafter the
smears were placed in xylene to remove alcohol and
finally were mounted with DPX and glass cover slips
were applied.
Immunocytochemistry of acetone fixed smears
The smears were fixed in cold acetone at 4°C for 10
m i n u t e sa n dd r i e da tr o o mt e m p e r a t u r e( R T )f o r1 0
minutes. After Tris-Buffered Saline (TBS) rehydration,
blocking of endogenous peroxidase activity with hydro-
gen peroxide (H2O2) was done for 30 minutes at RT.
Normal Horse Serum (NHS) diluted at 1:20 was then
applied for 30 minutes at RT. The excess NHS was
wiped off and slides incubated over night at 4°C with
primary antibodies [mouse monoclonal anti-human p53
(clone DO-7) (Dako, Glostrup, Denmark)]. After TBS
washing slides were then processed and mounted as
previously described [15,16].
Control of results
Negative controls included sections which did not
express the antigen under study and TBS instead of the
primary antibody. Positive controls consisted of sections
known to express the antigen under investigation.
Immunohistochemistry on paraffin control sections
This was done as previously described [15,16]. Five
microns (5 μ) thick sections were placed in xylene over
night for deparafinization, and hydrated in descending
grades of ethanol to distilled water. Antigen retrieval
was achieved by heating sections to boiling in Citrate
Buffer at pH 6.0 in a microwave oven for 10 minutes
and sections then allowed to cool to RT. The remainder
of the procedure was done as described above and pre-
viously [15,16].
Microscopy
The smears were finally evaluated in a Carl Zeiss Axio-
matic microscope (Jena, Germany) and digital micro-
photography was done using an Olympus Camera
Model DP 12 (Olympus Corporation, Japan) and pic-
tures processed using Adobe Photoshop 7.0 (Adobe Sys-
tems Incorporated, San Jose, USA).
Data collection and management
Patients’ identification, biodata and experimental results
were entered in structured and computer coded
questionnaires.
Data analysis
Data analysis was done using computer package; EPI
INFO 6 (CDC, Atlanta, Georgia, USA). P-values ≤ 0.05
was considered statistically significant.
Ethical issues
Ethical permission was sought from the MUHAS Ethical
Clearance Committee. Informed consent was sought
from patients to screen them for HIV and for cervical
cancer. Study participation/non-participation had no
bearing whatsoever on the quantity and/or quality of the
services the women expected to receive. All study infor-
mation was processed in confidence and patients’ IDs
were never exposed.
Study limitations
a) Cytological changes suggestive of HPV infection may
not reflect the true magnitude of HPV infection, since
molecular techniques to detect HPV were not done due
to logistical constrains.
b) Since only few cases were selected for p53 analysis,
the conclusion may not reflect the true extent of p53
inactivation by HPV.
Results
Demographic data of the patients
A total of 170 women were recruited from the two cen-
ters (120 HIV-seropositive cases on HAART from MNH
and 50 seronegative controls from ORCI) between 2005
and 2006. Singles constituted 64.1% (77/120) of cases
and only 26% (13/50) of controls. The rest of women in
each group were married which difference was highly
statistically significant (P-value < 0.001), suggesting that
singles were more likely to be HIV-infected (Figure 1
and Table 1). Age ranged from 20-66 years (mean 40.5
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Figure 1 The distribution of patients according to marital
status and HIV infection. Histograms showing the distribution of
patients according to marital status and HIV infection.
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Page 3 of 8years) among cases and from 20-69 years (mean 41.6
years) for Controls. The age group of 36-45 years was
the most affected (39.2%, 47/120) by HIV infection
(Table 1).
Distribution of cervical lesions
Cervicitis, squamous intraepithelial lesions (SIL) and
carcinoma constituted 28.3% (34/120), 38.3% (46/120)
and 5.8% (7/120) among cases, and 28% (14/50), 34%
(17/50) and 2% (1/50) for controls respectively, (P-value
= 0.6) [Figure 2 and Table 2]. A great majority (94.1%)
of cases with cervicitis (32/34) had acute cervicitis [bac-
terial vaginosis (Figure 3)] and only 2 (5.9%) had chronic
inflammation, and all HIV negative controls presented
with acute cervicitis (Table 2). In this study 9.4% of
smears of HIV infected patients with cervicitis showed
some cells with cytoplasmic inclusions, suggesting
Chlamydia infection (Figure 4). Furthermore, follicular
cervicitis was identified in two conventional smears of
HIV infected patients. A great majority (94.1%) of cases
with cervicitis (32/34) were single, while a lesser major-
ity (64.3%, 9/14) HIV negative controls were single (P-
value = 0.02), indicating that HIV infected patients on
HAART who are single were at an increased risk for
cervicitis compared with corresponding controls. The
same applied to the association of SIL and cervical can-
cer with marital status, number of sexual partners and
increased parity but not with the use of oral contracep-
tives (OC) were majority of cases and controls with the
conditions were non-OC users.
Majority (58.6%, 27/46) of SIL were LSIL (Figure 5)
and the rest were HSIL (Figure 6). However, a greater
majority (76.4%) of HIV negative controls had LSIL (13/
17) (P-value = 0.25) [Table 2]. Binucleated cells sugges-
tive of HPV or TV infections were present on 18.5% (5/
27) smears of HIV infected patients on HAART and
7.7% (1/13) smears of HIV negative control (Figure 5).
A great majority (85.7%, 6/7) of cases with carcinoma
had squamous cell carcinoma (SCC) but 1 (14.3%) had
adenocarcinoma (AC) [Figure 7]. Only one patient with
cervical malignancy amongst controls had SCC. Oran-
geophilic cells suggestive of keratinization, were found
in 66.6% (4/6) cases (Figure 7). The distribution of cyto-
logical features suggestive of HPV infection (koilocyto-
sis) between cases and controls was not statistically
significant (P-value = 0.76). However, this was more fre-
quent (77.8%, 21/27) in smears of cases older than 35
years but less so (55.6%, 5/9) of smears from controls.
Furthermore, a great majority (96.3%, 26/27) of cases
with cervical koilocytosis had had first sexual inter-
course before age 17 years but less so (77.8%, 7/9),
among controls (P-value = 0.02). This implies that an
early age of sexual debut increases the risk to HIV, HPV
and/or other STI.
Immunohistochemistry
This was performed on cell blocks and smears from the
cervix fixed in cold acetone for 13 cases of LSIL, 7 cases
of HSIL and 4 cases of carcinoma with cytomorphologi-
cal features suggestive of HPV infection. The expression
of p53 was absent in the tested slides compared with
the colorectal carcinoma used as positive control, in
which the expression of p53 was strong and nuclear in
location. These results suggest the ability of HPV onco-
genes (like E6) to interact with p53 although the sam-
ples tested were few.
Discussion
The increased frequency of cervical lesions generally
among adults in this study contrasted those of a pre-
vious study reporting a peak among adolescents and
Table 1 List of the general characteristics of the studied
Tanzanian women
Characteristics Cases Controls Combined P-
Value
HIV serostatus positive negative
Age-Range (years) 20-66 20-69 20-69
Mean Age (years) 40.5 41.6 41.05
Peak age-group (20-45years)
[No (%)]
84
(70.0)
33 (66.0) 117 (68.8) 0.700
Single [No (%)] 77
(64.1)
13 (26.0) 90 (52.9) <
0.001
Married [No (%)] 43
(35.8)
37 (74.0) 80 (47.1) <
0.001
Total number 120 50 170
This table shows that HIV infection was more frequent among singles
compared to married women and as expected, majority of HIV seropositive
women came from the most sexually active age-group of 20-45 years
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Figure 2 The distribution of cytological types of cervical
carcinoma and HIV status. This Histogram shows that squamous
cell carcinoma (SCC) as well as squamous intraepithelial lesions (SIL)
were more common amongst HIV seropositive women.
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Page 4 of 8young adults [17]. However, the discrepancy in the
results could be due to selection bias considering that
all our patients were recruited from the CTC, which is
mainly attended by patients older than 25 years on ART
and hence not representative of the general population.
In the present study the frequency of cervicitis among
HIV infected patients appears higher compared to a US
study where it was reported to be 15% [18]. The differ-
e n c em a yb ed u et ot h eh i g h e rp r e v a l e n c eo fH I Va n d
AIDS in sub-Saharan Africa (including Tanzania) com-
pared to USA [19,20].
That the HIV seropositive patients on HAART (cases)
were more likely to have SIL and invasive carcinoma of
the cervix than their corresponding controls seems in
part, to be related the increased risk behavior for STI
including HPV, HSV and in fact HIV among this group
as depicted by marital status (singles), number of life-
time sexual partners (multiple) and an early age at first
sexual intercourse [21-23]. A previous study showed
that inflammatory changes on cervical cytological
smears often indicate the presence of STI and masked
underlying premalignant disease of the cervix [24].
Due to limitations in resources, the isolation of Chla-
mydia in cell culture as well as the use of monoclonal
antibody to detect Chlamydia elementary bodies could
not be achieved in the current study. Nevertheless, our
index study indicated that features suggestive of Chla-
mydia cervicitis were more common among HIV
infected patients, which corroborates with several pre-
vious reports in which researchers reported that the
highest prevalence of Chlamydia trachomatis (CT) there
was found in HIV infected individuals [25,26]. CT is the
most common cause of STI and cytological changes in
Pap smears documented [25]. However, a previous study
reported that some Chlamydia negative patients had a
Pap test which was reported to contain inclusions con-
sistent with Chlamydia infection [27]. The author specu-
lated that the inclusions were probable aggregates of
bacteria, cell debris and/or other artifacts thus conclud-
ing that the Pap test has low sensitivity compared to
Chlamydia culture. Furthermore, follicular cervicitis
(FC) also identified in this study is reported to be asso-
ciated with CT infection [28].
Table 2 Distribution of cervicitis and SIL according to HIV serostatus
HIV
status
LSIL
No (%)
HSIL
No
(%)
Total SIL No
(%)
P-
Values
Acute Cervicitis No
(%)
Chronic Cervicitis No
(%)
Total Cervicitis No
(%)
Total Cervical
Lesions
P-
Values
HIV +ve 27(58.6) 19
(41.3)
46 (38.3) 0.25 32(94.1) 2(5.9) 34(28.3) 80(66.7) P =
0.61
HIV -ve 13(76,4) 4(23.5) 17(34.0) 0.25 14(100.0) 0(0.0) 14 (28.0) 31(62.0) P =
0.61
Total 40
(63.5)
23
(36.5)
63(56.8) 0.25 46(95.8) 2(4.2) 48(43.2) 111(100.0) P=
0.61
This table shows that the distribution of cervicitis did not vary with HIV serostatus and the distribution of HSIL appeared more likely to vary with HIV serostatus
compared to LSIL although both were not statistically significant
Figure 3 Pap smear showing bacterial vaginosis.Am i c r o g r a p h
showing Pap staining showing abundant clue cells (arrow)
suggestive of bacteria vaginosis more likely due to Gardnerella
vaginalis infection (× 40).
Figure 4 Pap smear showing Chlamydia cervicitis. Pap staining
in a patient with acute cervicitis showing a squamous cell with
cytopathic changes characterized by the presence of a cytoplasmic
inclusion body (arrow and inset) indicating Chlamydia infection (×
40).
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Page 5 of 8Squamous cell carcinoma was the most predominant
type of cancer found among HIV infected patients
which would be consistent with a concurrent HPV
infection as suggested in our results and would be in
agreement with a previous report indicating that HIV
alters the natural history of HPV infection, with
decreased regression rates and more rapid progression
to high grade and invasive lesions, which are refractory
to treatment, requiring more stringent intervention and
monitoring [5]. However, a previous report suggested a
high frequency of adenocarcinoma amongst HIV-
infected patients [29] and epidemiological and sample
population differences may explain the discrepancy.
However, both the current and the previous studies
report increasing frequency of amongst those aged ≥ 56
years as expected [29]. Cervical cancer in women
younger than 25 years is extremely rare [10]. HIV
infected women with cervical cancer before the age 35
years is considered an acquired AIDS-defining illness by
the Centers for Diseases Control (CDC) [5,30,31].
The relationship between high parity, OC use and cer-
vical cancer has been suggested and is probably attribu-
ted to hormonal factors [29,32].
Loss of wild-type p53 activity is an important event in
neoplastic transformation in cervical squamous epithe-
lium and is thought to occur by its degradation by the
E6 viral protein of HPV 16 and HPV 18 [33]. On the
basis of these mechanisms, clinically relevant p53 immu-
noreactivity would not be expected in HPV related cer-
vical carcinoma and SIL and this is shown in our
current study which also concurs with previous reports
suggesting that the expression of p53 is decreased in
lesions infected with intermediate and high risk HPV
due to the differential ability of HPV E6 proteins to
bind to and degrade p53 [33,34]. Thus the frequency,
distribution, risk factors and pathogenesis of cervical
lesions amongst a selected cohort of Tanzanian women,
have been further elucidated by our current study.
Conclusions
The cytological findings in this study suggest that the
frequency of SIL and carcinoma appeared to be higher
among HIV-infected women on HAART compared to
seronegative controls and as expected increased with
Figure 5 Pap smear showing LSIL. Pap staining in a patient with
LSIL showing extensive leukocytic background and a binucleated
parabasal squamous cell with mild nuclear enlargement and fine
granular chromatin (arrow and inset) suggestive of viral (HPV) or TV
infection (× 100).
Figure 6 Pap smear showing HSIL. Pap staining in a patient with
HSIL showing abundant neutrophils, a cluster of dendritic cells. The
arrows show a parabasal squamous cell with multiple cytoplasmic
vacuolation suggestive of viral infection (× 40).
Figure 7 Pap smear showing cervical cancer. Pap staining in a
patient with squamous carcinoma which exhibits clusters of
cohesive cells with marked nuclear enlargement, pleomorphisms,
hyperchromatism and keratinization (× 40).
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lier with SIL compared to those HIV seronegative sug-
gesting a role of HIV in altering the natural history of
HPV infection and cervical lesions. The absence of p53
immunoreactivity in HPV + lesions is indicative of the
ability of HPV E6 proteins to interact with the tumor
suppressor gene and pave way for viral-induced onco-
genesis in the studied Tanzanian women.
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